Interesting BMY Put And Call Options For December 2028

Bristol Myers Squibb (BMY) is presented with two option strategies: selling a $45 put (bid $5.80) which nets a $39.20 effective cost basis versus the current $54.48 share price, is ~17% out-of-the-money and has a 71% chance to expire worthless, implying a 12.89% return (4.33% annualized) on the cash commitment. A covered-call with a $57.50 strike (bid $7.45) on shares bought at $54.48 would cap upside at $57.50 but deliver a 19.22% total return if called by Dec 2028, with a 46% chance to expire worthless and a 13.67% YieldBoost (4.59% annualized). Implied volatilities are ~31% on the put and 30% on the call, versus a trailing 12-month volatility of 29%, and the publisher will track odds and contract histories on its site.

Analysis

Market structure: The option chain implies income-seeking flow benefits option sellers and yield strategies on BMY (collecting ~12.9% cash yield if put expires), while holders of high-upside, uncapped bets (long stock without calls) are disadvantaged by potential covered-call monetization. The near parity of IV (30–31%) and realized vol (29%) signals limited skew — market participants are not pricing large binary pharma tail risk, which keeps bid for protection muted and compresses hedging costs. Cross-asset: a material BMY shock (>20–30%) would feed into sector IV, transiently raise corporate credit spreads for peers and boost safety bids in Treasuries; FX/commodities impact is negligible.

Risk assessment: Tail risks are classic pharma binaries — adverse FDA rulings, Phase III failures, patent loss, or large litigation could cause >30% moves and blow through the $45/$57.50 strikes; implied odds (71% put worthless, 46% call worthless) understate single-event skew. Immediate (days) risk centers on any upcoming trial/FDA/earnings windows; short-term (weeks–months) risks are IV re-pricing and assignment; long-term (years) depends on pipeline outcomes and M&A. Hidden dependencies: sellers assume assignment liquidity and capital to buy 100-share lots; margin shocks and forced deleveraging are second-order risks.

Trade implications: For yield-focused allocations, selling the Dec‑2028 $45 put for $5.80 is attractive only if willing to own at $39.20 — size at 1–3% portfolio cash and hedge with a buy $40 put to create a defined-risk credit spread if downside risk >20% is unacceptable. Covered-call (buy 100 BMY, sell Dec‑2028 $57.50 for $7.45) offers ~19.2% to callaway; limit to 1–3% equity allocation and plan to roll if BMY > $60 or IV rises >5ppt. If seeking directional long with protection, buy shares and purchase 1–2pt OTM puts (3–6 month expiries) to cap event risk.

Contrarian angles: Consensus income math ignores asymmetric pharma binaries — the ~4.3–4.6% annualized YieldBoost may undercompensate for a single negative catalyst; this suggests risk-adjusted yields are likely mispriced if an FDA event lands within 12 months. Historically, selling puts ahead of binary events often results in outsized losses despite attractive theta; complacent IV vs realized vol suggests a short-vol stance should be size-constrained and hedged. Unintended consequence: assignment can force cash purchases at $45, creating opportunity-cost and forced selling elsewhere during market stress.

Key Decisions for Investors

• Sell-to-open 1 Dec‑2028 BMY $45 put for $5.80 (collect $580) only if you are willing to own 100 shares at $39.20; size at 1–3% of portfolio cash. Immediately buy a Dec‑2028 $40 put as hedge (defined-risk credit spread) if you want to cap downside to limit max loss to <$600–$1,000 per contract equivalent.
• Establish a covered-call position: buy 100 BMY at market ($54.48) and sell Dec‑2028 $57.50 call for $7.45 to lock ~19.2% gross to callaway; allocate 1–3% portfolio and plan to roll up/forward if BMY > $60 or IV increases >5 percentage points.
• If directional long but risk-averse, buy 100 BMY and purchase 3–6 month 5–7% OTM puts (protective collars) before any known catalyst windows (FDA, earnings). Exit/reevaluate within 48 hours of any negative trial or regulatory headline.
• Avoid naked short-vol in BMY or the large-cap pharma bucket: cap aggregate short option exposure to <2% portfolio and force automatic unwind if IV spikes +10 pts or stock moves >15% intraday to avoid tail gamma/call risk.